# Eli Lilly 10% Growth by 2030

> How $1,000 invested in Eli Lilly at 10% annual growth becomes by 2030.
- Title: Eli Lilly 10% Growth by 2030 · 24/7 Wall St. | Shortify
- Summary: How $1,000 invested in Eli Lilly at 10% annual growth becomes by 2030. A $1,000 investment in Eli Lilly grows to $1,830.10 by 2031 at 10% annual growth.
- Keywords: eli lilly, 10% growth, 2030, stock investment, revenue growth, weight-loss drugs, mounjaro, zepbound, Eli, Lilly, Growth, 24/7 Wall St.
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/20/if-eli-lilly-grows-at-10-a-year-heres-what-1000-becomes-by-2030
- Author: Vandita Jadeja
- Published: 2026-10-20T15:30:39+00:00
- Read time: 1 min
- Topics: eli lilly, 10% growth, 2030, stock investment, revenue growth, weight-loss drugs, mounjaro, zepbound
## Eli Lilly Revenue Growth
Eli Lilly reported 47.7% revenue growth year over year in Q2 2026.

> Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare
## Starting Price for 2030 Projection
The model starts with a $1,208.74 share price as the base for 2030 calculations.

> In intraday trading the shares were at $1,267.90, up 4.89% on the session from $1,208.74
## 10% Annual Growth Projection
A $1,000 investment grows to $1,830.10 by 2031 at 10% annual growth.

> In its base case, a $1,000 investment would increase to about $1,830.10 by 2031, a total return of 83.01%
## Bull, Base and Bear Scenarios
Bull case: $2,227.90 value for $1,000 by 2030. Base case: $1,830.10. Bear case: $1,205.

> Bull: $2,693, 122.79% return, $2,227.90 value. Base: $2,212.06, 83.01% return, $1,830.10 value. Bear: $1,456.52, 20.5% return, $1,205 value
## Weight-Loss Drug Performance
Mounjaro generated $9.94 billion in Q2, up 91%, with international sales rising 172% after China's National Reimbursement Drug List inclusion.

> Mounjaro brought in $9.94 billion in the second quarter, up 91%. International sales rose 172% after the drug was added to China’s National Reimbursement Drug List
## Earnings and Guidance
Q2 EPS of $8.38 exceeded estimates, with full-year 2026 revenue guidance raised to $87 billion.

> Q2 EPS of $8.38 exceeded the $6.58 estimate, giving Lilly 5 consecutive beats. Management raised full-year 2026 revenue guidance to $85 billion to $87 billion, up from $82 billion to $85 billion
## Future Drug Pipeline
Lilly plans to file retatrutide in Q1 2027 and launch oral GLP-1 Foundayo in 2027 with over 40 phase three programs.

> Lilly plans to file retatrutide in quarter one, 2027. The oral GLP-1 Foundayo is set for a global launch in 2027, and the company has more than 40 active phase three programs
## Risks to 2030 Projection
Pricing pressures, competition from Novo Nordisk, and valuation at a trailing P/E of 40 could reduce 2030 returns.

> Pricing is the biggest pressure point. Realized prices fell 13% in Q2, while a 60% jump in volume did the heavy lifting. Acquired IPR&D charges of $2.78 billion in the quarter led management to lower the top of its EPS guidance to $36.50 from $37. Mounjaro and Zepbound make up the majority of revenue, so any slowdown in that franchise would hit the whole company.
## Key takeaway

A $1,000 investment in Eli Lilly grows to $1,830.10 by 2031 at 10% annual growth.